Follow
Oded Edelheit, Ph.D.
Oded Edelheit, Ph.D.
NovellusDx
Verified email at progen.co.il
Title
Cited by
Cited by
Year
Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies
O Edelheit, A Hanukoglu, I Hanukoglu
BMC biotechnology 9, 1-8, 2009
4342009
Epithelial sodium channels (ENaC) are uniformly distributed on motile cilia in the oviduct and the respiratory airways
Y Enuka, I Hanukoglu, O Edelheit, H Vaknine, A Hanukoglu
Histochemistry and cell biology 137, 339-353, 2012
1292012
Novel mutations in epithelial sodium channel (ENaC) subunit genes and phenotypic expression of multisystem pseudohypoaldosteronism
O Edelheit, I Hanukoglu, M Gizewska, N Kandemir, ...
Clinical Endocrinology 62 (5), 547-553, 2005
1002005
Renin–aldosterone response, urinary Na/K ratio and growth in pseudohypoaldosteronism patients with mutations in epithelial sodium channel (ENaC) subunit genes
A Hanukoglu, O Edelheit, Y Shriki, M Gizewska, N Dascal, I Hanukoglu
The Journal of steroid biochemistry and molecular biology 111 (3-5), 268-274, 2008
712008
Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer
N Peled, LC Roisman, B Miron, R Pfeffer, RB Lanman, M Ilouze, A Dvir, ...
Journal of Thoracic Oncology 12 (7), e81-e84, 2017
542017
Truncated beta epithelial sodium channel (ENaC) subunits responsible for multi-system pseudohypoaldosteronism support partial activity of ENaC
O Edelheit, I Hanukoglu, Y Shriki, M Tfilin, N Dascal, D Gillis, A Hanukoglu
The Journal of Steroid Biochemistry and Molecular Biology 119 (1-2), 84-88, 2010
382010
Identification of the roles of conserved charged residues in the extracellular domain of an epithelial sodium channel (ENaC) subunit by alanine mutagenesis
O Edelheit, I Hanukoglu, N Dascal, A Hanukoglu
American Journal of Physiology-Renal Physiology 300 (4), F887-F897, 2011
322011
Conserved charged residues at the surface and interface of epithelial sodium channel subunits–roles in cell surface expression and the sodium self‐inhibition response
O Edelheit, R Ben‐Shahar, N Dascal, A Hanukoglu, I Hanukoglu
The FEBS Journal 281 (8), 2097-2111, 2014
292014
Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations.
JM Loree, B Miron, V Holla, MJ Overman, AAL Pereira, M Lam, VK Morris, ...
Journal of Clinical Oncology 35 (15_suppl), 3589-3589, 2017
132017
Revisited analysis of a SHIVA 01 trial cohort using functional mutational analyses successfully predicted treatment outcome
M Kamal, G Tarcic, S Dureau, O Edelheit, Z Barbash, C Lecerf, C Morel, ...
Molecular Oncology 12 (5), 594-601, 2018
62018
Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance (VUS) detected in patients included in the SHIVA trial
G Tarcic, M Kamal, O Edelheit, Z Barbash, M Vidne, B Miron, C Callens, ...
European Journal of Cancer 1 (69), S6-S7, 2016
22016
Functional characterization of mutations and their interaction using the novel functional annotation for cancer treatment (FACT) platform
B Miron, N Peled, Z Barbash, O Edelheit, M Vidne, R Sharivkin, G Tarcic
Annals of Oncology 27, vi404, 2016
12016
Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025)-interim results
B Miron, N Peled, G Tarcic, Z Barbash, O Edelheit, M Vidne, MR Kramer
Annals of Oncology 27, vi412, 2016
12016
Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis successfully predicted treatment outcome
G Tarcic, C Le Tourneau, M Kamal, O Edelheit, Z Barbash, M Vidne, ...
Annals of Oncology 28, v450-v451, 2017
2017
Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC)
B Miron, G Tarcic, O Edelheit, N Burck, M Vidne, L Roisman, N Peled
CANCER RESEARCH 77, 2017
2017
Abstract LB-041: Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC)
B Miron, G Tarcic, O Edelheit, N Burck, M Vidne, L Roisman, N Peled
Cancer Research 77 (13_Supplement), LB-041-LB-041, 2017
2017
Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD)
G Tarcic, CM Walko, HL McLeod, JK Hicks, Z Barbash, O Edelheit, ...
Annals of Oncology 27, vi403, 2016
2016
Functional characterization of VUS mutations found in patients' cell-free circulating tumor DNA (ctDNA) using Precision Cancer Analysis System (PCAS).
G Tarcic, DA Simon, M Jacobstein, RB Lanman, M Vidne, Z Barbash, ...
Journal of Clinical Oncology 34 (15_suppl), 11576-11576, 2016
2016
Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025): Interim results.
G Tarcic, N Peled, Z Barbash, O Edelheit, M Vidne, MR Kramer
Journal of Clinical Oncology 34 (15_suppl), e20066-e20066, 2016
2016
Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram).
RJ Sullivan, Z Barbash, O Edelheit, M Vidne, JA Sosman, K Flaherty, ...
Journal of Clinical Oncology 34 (15_suppl), 9537-9537, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–20